Michal Šmída

Publications that are part of the Web of Science database, possibly also other publications chosen by authors.

2021

• Mancikova, V; Smida, M, 2021: Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 22(11), doi: 10.3390/ijms22115536

2020

• Kozlova, V; Ledererova, A; Ladungova, A; Peschelova, H; Janovska, P; Slusarczyk, A; Domagala, J; Kopcil, P; Vakulova, V; Oppelt, J; Bryja, V; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2020: CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. PLOS ONE 15(3), doi: 10.1371/journal.pone.0229170
• Mancikova, V; Peschelova, H; Kozlova, V; Ledererova, A; Ladungova, A; Verner, J; Loja, T; Folber, F; Mayer, J; Pospisilova, S; Smida, M, 2020: Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. JOURNAL FOR IMMUNOTHERAPY OF CANCER 8(1), doi: 10.1136/jitc-2019-000471
• Kozlova, V; Ledererova, A; Mancikova, V; Mayer, J; Pospisilova, S; Doubek, M; Smida, M, 2020: Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. LEUKEMIA & LYMPHOMA 61, p. 256 - 257

2018

• Kozlova, V; Ledererova, A; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2018: Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies. BLOOD 132, doi: 10.1182/blood-2018-99-118669

2017

• Ledererova, A; Kozlova, V; Vakulova, V; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2017: B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE. HAEMATOLOGICA 102, p. 709 - 709
• de la Cruz, FF; Smida, M; Nijman, S, 2017: MEK inhibitors block growth of Ataxia Telangiectasia Mutated (ATM) mutant lung tumors. MOLECULAR CANCER THERAPEUTICS 16(10), doi: 10.1158/1538-8514.SYNTHLETH-PR14

2016

• Smida, M; Kozlova, V; Vakulova, V; Ledererova, A; Doubek, M; Mayer, J; Pospisilova, S, 2016: Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy in B-Lymphoid Malignancies. BLOOD 128(22)
• Smida, M; de la Cruz, FF; Kerzendorfer, C; Uras, IZ; Mair, B; Mazouzi, A; Suchankova, T; Konopka, T; Katz, AM; Paz, K; Nagy-Bojarszky, K; Muellner, MK; Bago-Horvath, Z; Haura, EB; Loizou, JI; Nijman, SMB, 2016: MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. NATURE COMMUNICATIONS 7, doi: 10.1038/ncomms13701

2015

• Šmída, M, 2015: Chimérický antigenní receptor T lymfocytů- genová terapie budoucnosti u nádorových onemocnění?. KLINICKÁ ONKOLOGIE
• Doubek, M; Smida, M, 2015: Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. EXPERT REVIEW OF HEMATOLOGY 8(6), p. 743 - 764, doi: 10.1586/17474086.2015.1079123

• Národní centrum lékařské genomiky (LM2015091), Ministerstvo školství, mládeže a tělovýchovy ČR, 2016 - 2019
• Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie (15-33561A), Ministry of Health of the CR, 2015 - 2018